Oral extended release formulation of gepirone
CA 2436692 A1 · Owner: Akzo Nobel Nv · Inventors: Egberink, Johannes Gerardus Joseph; Engelhart, John Francis
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention makes a pharmaceutical formulation for oral administration with extended release properties available comprising an amount of gepirone hydrochloride, an amount of a cellulosic polymer matrix and an amount of microcrystalline cellulose characterised in that the amount the pharmaceutically acceptable cellulosic polymer matrix is from 70 to 85 wt% the amount of carbohydrate binder is from 7 to 10 wt% and the amount of gepirone hydrochloride is from 13 to 21 wt%. The formulation is useful for a treatment for depression or a related central nervous system disorder with gepirone administered in a once-a-day oral formulation for extended release of gepirone.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 30, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 30, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 30, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.